vergelabs-com/
26 pages · Updated July 18, 2026
Pages
- reports
- Introducing vBx-1.0 | Reports | Verge Labs
- Privacy Policy | Verge Labs
- Resources | Verge Labs
- Positive Phase 1 safety and tolerability data for VRG50635 | News | Verge Labs
- Publications | Verge Labs
- First-in-human dosing of VRG50635 begins in Phase 1 trial | News | Verge Labs
- Partnerships | Verge Labs
- Mission | Company | Verge Labs
- New approach for uncovering novel drug targets from human genetics published in PLOS Computational Biology | News | Verge Labs
- Fierce Biotech names Verge Genomics a 2022 “Fierce 15” biotech company | News | Verge Labs
- Verge Genomics and Eli Lilly announce three-year ALS collaboration | News | Verge Labs
- Verge Genomics and the Pritzker Consortium form schizophrenia research collaboration | News | Verge Labs
- Alice Zhang honored by Goldman Sachs as one of 2022’s Most Exceptional Entrepreneurs | News | Verge Labs
- Verge Genomics and Alexion launch AI-enabled drug discovery collaboration for rare neuro diseases | News | Verge Labs
- Verge Labs Unveils vBx: A Breakthrough Foundation Model for Precision Neurology | News | Verge Labs
- Alice Zhang named to Fortune 40 Under 40 and Fierce Biotech’s Fiercest Women in Life Sciences | News | Verge Labs
- Lilly selects two ALS targets from CONVERGE® collaboration | News | Verge Labs
- Verge Labs and Tenacia Biotechnology Partner to Advance Tenacia’s CNS Pipeline Using Human Data | News | Verge Labs
- Applications | Platform | Verge Labs
- Digital biomarkers detect short-term ALS progression in VRG50635 trial run-in | News | Verge Labs
- VRG50635 proof-of-concept study initiated in patients with ALS | News | Verge Labs
- Data | Platform | Verge Labs
- Models | Platform | Verge Labs
- Blog | Verge Labs
- News | Verge Labs